Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 5/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | TXK | P42681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20480742 | 1.00 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBPIK3CGNPSR1 | |
| SCHEMBL15155889 | 0.94 | EGFR (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGNPSR1 | |
| SCHEMBL15711178 | 0.88 | JAK2 (0.49) | PIK3CDBTK | |
| SCHEMBL28076558 | 0.86 | CALCRL (0.40) | CALCRLOPRM1OPRK1OPRL1BCHE | |
| SCHEMBL28076562 | 0.86 | CALCRL (0.40) | CALCRLOPRM1OPRK1OPRL1BCHE | |
| SCHEMBL29487294 | 0.86 | BTK (0.38) | NPSR1KDM4EBTKLCKOPRK1 | |
| SCHEMBL25167958 | 0.85 | NPSR1 (0.41) | NPSR1KDM4EMAPTOPRM1OPRK1 | |
| SCHEMBL16341186 | 0.83 | HTR6 (0.46) | BTKBCHE | |
| SCHEMBL15171260 | 0.83 | HTR6 (0.46) | BTKBCHE | |
| SCHEMBL14797959 | 0.83 | JAK1 (0.42) | PIK3CDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-20 | — | — | US | disclosed |
| US-11897885-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| CN-115304606-A | Degradation agent for simultaneously targeting BTK and GSPT1 proteins | 清华大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20220177474-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-11292795-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-04-05 | — | — | US | disclosed |
| US-20210346382-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2021-11-11 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| US-11154554-B2 | Therapeutic combinations of a MEK inhibitor and a BTK inhibitor | Acera Pharma B.V. (NL) | 2021-10-26 | — | — | US | disclosed |
| US-9371325-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-21 | — | — | US | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024228-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024227-A1 | BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024232-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024231-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| US-9199997-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150274731-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20140330015-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD (JP) | 2014-11-06 | — | — | US | disclosed |
| EP-2786996-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330015-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | PIK3CD 433/4885PIK3CA 448/4885PIK3CB 276/4885 |
| US-11292795-B2 | Purinone derivative hydrochloride | BTK, P2RY1, P2RY13 | PIK3CD 433/4885PIK3CA 448/4885PIK3CB 276/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | PIK3CD 10/4885PIK3CA 33/4885PIK3CB 31/4885 |
| US-20220177474-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | PIK3CD 433/4885PIK3CA 448/4885PIK3CB 276/4885 |
| US-11154554-B2 | Therapeutic combinations of a MEK inhibitor and a BTK inhibitor | BTK, BRAF, LCK | PIK3CD 79/4885PIK3CA 44/4885PIK3CB 107/4885 |
| US-20150274731-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | PIK3CD 433/4885PIK3CA 448/4885PIK3CB 276/4885 |
| US-11897885-B2 | Purinone derivative hydrochloride | BTK, P2RY1, P2RY13 | PIK3CD 433/4885PIK3CA 448/4885PIK3CB 276/4885 |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | BTK, LYN, SYK | PIK3CD 315/4885PIK3CA 304/4885PIK3CB 248/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | PIK3CD 10/4885PIK3CA 33/4885PIK3CB 31/4885 |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | BTK, CD274, BCL9 | PIK3CD 190/4885PIK3CA 200/4885PIK3CB 206/4885 |
| US-20210346382-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | BTK, LYN, SYK | PIK3CD 315/4885PIK3CA 304/4885PIK3CB 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.